Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN.

Lancet Oncol. 2018 Nov 12. pii: S1470-2045(18)30578-3. doi: 10.1016/S1470-2045(18)30578-3. [Epub ahead of print]

PMID:
30442501
2.

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

Siebert N, Troschke-Meurer S, Marx M, Zumpe M, Ehlert K, Gray J, Garaventa A, Manzitti C, Ash S, Klingebiel T, Beck J, Castel V, Valteau-Couanet D, Loibner H, Ladenstein R, Lode HN.

Cancers (Basel). 2018 Oct 17;10(10). pii: E387. doi: 10.3390/cancers10100387.

3.

Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.

Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, Kim K, Loibner H, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2018 Oct;67(10):1647-1658. doi: 10.1007/s00262-018-2223-z. Epub 2018 Aug 3.

PMID:
30073390
4.

Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites.

Morris ZS, Guy EI, Werner LR, Carlson PM, Heinze CM, Kler JS, Busche SM, Jaquish AA, Sriramaneni RN, Carmichael LL, Loibner H, Gillies SD, Korman AJ, Erbe AK, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM.

Cancer Immunol Res. 2018 Jul;6(7):825-834. doi: 10.1158/2326-6066.CIR-17-0353. Epub 2018 May 10.

PMID:
29748391
5.

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN.

MAbs. 2018 Jan;10(1):55-61. doi: 10.1080/19420862.2017.1402997. Epub 2017 Dec 5.

6.

The Combyn™ ECG: Adding haemodynamic and fluid leads for the ECG. Part II: Prediction of total body water (TBW), extracellular fluid (ECF), ECF overload, fat mass (FM) and "dry" appendicular muscle mass (AppMM).

Skrabal F, Pichler GP, Penatzer M, Steinbichl J, Hanserl AK, Leis A, Loibner H.

Med Eng Phys. 2017 Jun;44:44-52. doi: 10.1016/j.medengphy.2017.03.002. Epub 2017 Mar 31.

PMID:
28373014
7.

Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.

Rakhmilevich AL, Felder M, Lever L, Slowinski J, Rasmussen K, Hoefges A, Van De Voort TJ, Loibner H, Korman AJ, Gillies SD, Sondel PM.

J Immunol. 2017 Feb 15;198(4):1575-1584. doi: 10.4049/jimmunol.1601255. Epub 2017 Jan 6.

8.

Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors.

Hintersteiner B, Lingg N, Zhang P, Woen S, Hoi KM, Stranner S, Wiederkum S, Mutschlechner O, Schuster M, Loibner H, Jungbauer A.

MAbs. 2016 Nov/Dec;8(8):1548-1560. Epub 2016 Aug 25.

9.

Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.

Hintersteiner B, Lingg N, Janzek E, Mutschlechner O, Loibner H, Jungbauer A.

Biotechnol J. 2016 Dec;11(12):1617-1627. doi: 10.1002/biot.201600504. Epub 2016 Nov 22.

PMID:
27753240
10.

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, Weiss M, Loibner H, Ladenstein R, Lode HN.

MAbs. 2016;8(3):604-16. doi: 10.1080/19420862.2015.1130196. Epub 2016 Jan 19.

11.

Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.

Suppan C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, Eberhard K, Samonigg H, Loibner H, Dandachi N, Balic M.

BMC Cancer. 2015 Dec 29;15:1027. doi: 10.1186/s12885-015-2005-3.

12.

Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer.

Absenger G, Szkandera J, Stotz M, Postlmayr U, Pichler M, Ress AL, Schaberl-Moser R, Loibner H, Samonigg H, Gerger A.

Anticancer Res. 2013 Oct;33(10):4591-4.

PMID:
24123035
13.

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M.

Br J Cancer. 2013 Jul 23;109(2):416-21. doi: 10.1038/bjc.2013.332. Epub 2013 Jun 25. Erratum in: Br J Cancer. 2013 Oct 1;109(7):2026. Zoughbi, W [corrected to AlZoughbi, W].

14.

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects.

Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krähenbühl S.

Clin Pharmacokinet. 2013 Sep;52(9):783-92. doi: 10.1007/s40262-013-0072-7.

PMID:
23681967
15.

Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.

Hinterleitner R, Gruber T, Pfeifhofer-Obermair C, Lutz-Nicoladoni C, Tzankov A, Schuster M, Penninger JM, Loibner H, Lametschwandtner G, Wolf D, Baier G.

PLoS One. 2012;7(9):e44295. doi: 10.1371/journal.pone.0044295. Epub 2012 Sep 4.

16.

Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System.

Poglitsch M, Domenig O, Schwager C, Stranner S, Peball B, Janzek E, Wagner B, Jungwirth H, Loibner H, Schuster M.

Int J Hypertens. 2012;2012:428950. doi: 10.1155/2012/428950. Epub 2012 Feb 28.

17.

Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia.

Kleinsasser A, Pircher I, Treml B, Schwienbacher M, Schuster M, Janzek E, Loibner H, Penninger JM, Loeckinger A.

Wilderness Environ Med. 2012 Mar;23(1):24-30. doi: 10.1016/j.wem.2011.09.002.

PMID:
22441085
18.

Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury.

Rey-Parra GJ, Vadivel A, Coltan L, Hall A, Eaton F, Schuster M, Loibner H, Penninger JM, Kassiri Z, Oudit GY, Thébaud B.

J Mol Med (Berl). 2012 Jun;90(6):637-47. doi: 10.1007/s00109-012-0859-2. Epub 2012 Jan 14.

PMID:
22246130
19.

Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.

Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, Loibner H, Bai S, Blackwell TR, Tada Y, Harral JW, Talati M, Lane KB, Fagan KA, West J.

Am J Physiol Lung Cell Mol Physiol. 2012 Mar 1;302(5):L474-84. doi: 10.1152/ajplung.00202.2011. Epub 2011 Dec 16.

20.

Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2.

Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, Oudit GY.

Hypertension. 2011 Feb;57(2):314-22. doi: 10.1161/HYPERTENSIONAHA.110.164244. Epub 2010 Dec 28.

PMID:
21189404
21.

Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression.

Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, Gao PJ, Huang DY, Shuster M, Loibner H, Guo JM, Yu XY, Xiao BX, Gong ZH, Penninger JM, Oudit GY.

Regul Pept. 2011 Jan 17;166(1-3):90-7. doi: 10.1016/j.regpep.2010.09.005. Epub 2010 Sep 18.

PMID:
20854846
22.

Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.

Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY.

Circulation. 2010 Aug 17;122(7):717-28, 18 p following 728. doi: 10.1161/CIRCULATIONAHA.110.955369. Epub 2010 Aug 2.

PMID:
20679547
23.

Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.

Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Batlle D.

Hypertension. 2010 Jan;55(1):90-8. doi: 10.1161/HYPERTENSIONAHA.109.138420. Epub 2009 Nov 30.

24.

Human recombinant ACE2 reduces the progression of diabetic nephropathy.

Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW.

Diabetes. 2010 Feb;59(2):529-38. doi: 10.2337/db09-1218. Epub 2009 Nov 23. Erratum in: Diabetes. 2010 Apr;59(4):1113-4.

25.

Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets.

Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, Schuster M, Janzek E, Loibner H, Penninger J, Loeckinger A.

Crit Care Med. 2010 Feb;38(2):596-601. doi: 10.1097/CCM.0b013e3181c03009.

PMID:
19851091
26.

Exit-site care in Austrian peritoneal dialysis centers -- a nationwide survey.

Kopriva-Altfahrt G, König P, Mündle M, Prischl F, Roob JM, Wiesholzer M, Vychytil A; Austrian Study Group for Prevention of Peritoneal Catheter-Associated Infections, Arneitz K, Karner A, Artes R, Wolf E, Auinger M, Pawlak A, Fraberger J, Hofbauer S, Galvan G, Salmhofer H, Pichler B, Wazel M, Gruber M, Thonhofer A, Hager A, Malajner S, Heiss S, Braunsteiner T, Zweiffler M, König P, Rudnicki M, Kogler R, Kohlhauser D, Wiesinger T, Kopriva-Altfahrt G, Moser E, Kotanko P, Loibner H, Nitz H, Miska HJ, Wenzel R, Wölfer M, Mündle M, Breuss H, Hölzl B, Prischi F, Schmekal B, Riener EM, Roob JM, Wonisch W, Vikydal R, Vychytil A, Frank B, Wieser C, Wiesholzer M, Pokorny K.

Perit Dial Int. 2009 May-Jun;29(3):330-9.

PMID:
19458307
27.

Yeast cell surface display system for determination of humoral response to active immunization with a monoclonal antibody against EpCAM.

Dürauer A, Berger E, Zandian M, Mersich C, Schuster M, Loibner H, Jungbauer A.

J Biochem Biophys Methods. 2008 Apr 24;70(6):1109-15. doi: 10.1016/j.jprot.2008.01.008. Epub 2008 Jan 24.

PMID:
18321588
28.

A clinical development paradigm for cancer vaccines and related biologics.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group.

J Immunother. 2007 Jan;30(1):1-15. Review.

PMID:
17198079
29.

Peptide arrays for the determination of humoral responses induced by active immunization with a monoclonal antibody against EpCAM.

Dürauer A, Berger E, Schuster M, Wasserbauer E, Himmler G, Loibner H, Mudde GC, Jungbauer A.

J Immunol Methods. 2006 Dec 20;317(1-2):114-25. Epub 2006 Oct 9.

PMID:
17069841
30.

Immunization of Rhesus monkeys with a SialylTn-mAb17-1A conjugate vaccine co-formulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells.

Kircheis R, Siegl P, Grunt S, Halanek N, Loibner H, Mudde GC, Nechansky A.

Cancer Immunol Immunother. 2007 Jun;56(6):863-73. Epub 2006 Sep 29.

PMID:
17009044
31.

Immunization of Rhesus monkeys with the conjugate vaccine IGN402 induces an IgG immune response against carbohydrate and protein antigens, and cancer cells.

Kircheis R, Vondru P, Zinöcker I, Häring D, Nechansky A, Loibner H, Mudde GC.

Vaccine. 2006 Mar 20;24(13):2349-57. Epub 2005 Dec 12.

PMID:
16406172
32.

SialylTn-mAb17-1A carbohydrate-protein conjugate vaccine: effect of coupling density and presentation of SialylTn.

Kircheis R, Vondru P, Nechansky A, Ohler R, Loibner H, Himmler G, Mudde GC.

Bioconjug Chem. 2005 Nov-Dec;16(6):1519-28.

PMID:
16287250
33.

Comparison of two methods for enumerating circulating tumor cells in carcinoma patients.

Balic M, Dandachi N, Hofmann G, Samonigg H, Loibner H, Obwaller A, van der Kooi A, Tibbe AG, Doyle GV, Terstappen LW, Bauernhofer T.

Cytometry B Clin Cytom. 2005 Nov;68(1):25-30.

34.

Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.

Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C, Waxenecker G, Wiederkum S, Schwager C, Loibner H, Himmler G, Mudde GC.

Cancer Res. 2005 Sep 1;65(17):7934-41.

35.

Heterogeneous alterations in human alloimmunity associated with immunization.

Roddy M, Clemente M, Poggio ED, Bukowski R, Thakkar S, Waxenecker G, Loibner H, Himmler G, Hricik DE, Heeger PS.

Transplantation. 2005 Aug 15;80(3):297-302.

PMID:
16082322
36.

[Immunotherapy of malignant diseases--developments and prospects].

Paukovits P, Himmler G, Loibner H.

Wien Med Wochenschr. 2004 May;154(9-10):235-41. Review. German.

PMID:
15244049
37.

Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors.

Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V.

Cancer Res. 2004 Feb 1;64(3):1087-93.

38.

Increased expression of the blood group-related Lewis Y antigen on synovial fluid granulocytes of patients with arthritic joint diseases.

Dettke M, Pálfi G, Pursch E, Fischer MB, Loibner H.

Rheumatology (Oxford). 2001 Sep;40(9):1033-7.

PMID:
11561115
39.
41.

A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.

Samonigg H, Wilders-Truschnig M, Kuss I, Plot R, Stöger H, Schmid M, Bauernhofer T, Tiran A, Pieber T, Havelec L, Loibner H.

J Immunother. 1999 Nov;22(6):481-8.

PMID:
10570746
42.

Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys.

Co MS, Baker J, Bednarik K, Janzek E, Neruda W, Mayer P, Plot R, Stumper B, Vasquez M, Queen C, Loibner H.

Cancer Res. 1996 Mar 1;56(5):1118-25.

43.
44.

Enhancement of retroviral infection in vitro by anti-Le(y) IgG: reversal by humanization of monoclonal mouse antibody.

Hansen JE, Sørensen AM, Arendrup M, Olofsson S, Nielsen JO, Janzek E, Nielsen C, Loibner H.

APMIS. 1993 Sep;101(9):711-8.

PMID:
7902106
45.

Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody.

Samonigg H, Wilders-Truschnig M, Loibner H, Plot R, Rot A, Kuss I, Werner G, Stöger H, Wrann M, Herlyn D, et al.

Clin Immunol Immunopathol. 1992 Dec;65(3):271-7.

PMID:
1451329
46.

Enzymatic synthesis and comparative biological evaluation of a phosphonate analogue of the lipid A precursor.

Scholz D, Bednarik K, Ehn G, Neruda W, Janzek E, Loibner H, Briner K, Vasella A.

J Med Chem. 1992 May 29;35(11):2070-4.

PMID:
1597857
47.

Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer.

Stahel RA, Lacroix H, Sculier JP, Morant R, Richner J, Janzek E, Loibner H, Blythman H.

Ann Oncol. 1992 Apr;3(4):319-20. No abstract available.

PMID:
1327079
49.

Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide.

Steplewski Z, Lubeck MD, Scholz D, Loibner H, McDonald Smith J, Koprowski H.

In Vivo. 1991 Mar-Apr;5(2):79-83.

PMID:
1768791
50.

Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies.

Scholz D, Lubeck M, Loibner H, McDonald-Smith J, Kimoto Y, Koprowski H, Steplewski Z.

Cancer Immunol Immunother. 1991;33(3):153-7.

PMID:
2044080

Supplemental Content

Loading ...
Support Center